TScan Therapeutics annual current ratio
2020
2021
2022
2023
2024
2025
TScan Therapeutics Current Ratio Growth & History (TCRX)
TScan Therapeutics's current ratio was 8.41 for fiscal 2025.
View full TScan Therapeutics company overviewTScan Therapeutics annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 8.41 | 0.27 | +3.29% |
| 2024 | 2024-12-31 | 8.14 | 1.63 | +24.99% |
| 2023 | 2023-12-31 | 6.51 | −0.66 | −9.19% |
| 2022 | 2022-12-31 | 7.17 | −0.59 | −7.58% |
| 2021 | 2021-12-31 | 7.76 | 5.67 | +271.54% |
| 2020 | 2020-12-31 | 2.09 | — | — |
TScan Therapeutics quarterly current ratio
Q4.20
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 3.37 | −3.69 | −52.24% |
| Q1 2026 | 2026-03-31 | 6.65 | −1.90 | −22.21% |
| Q4 2025 | 2025-12-31 | 8.41 | 0.27 | +3.29% |
| Q3 2025 | 2025-09-30 | 6.44 | −3.12 | −32.64% |
| Q2 2025 | 2025-06-30 | 7.06 | −0.71 | −9.09% |
| Q1 2025 | 2025-03-31 | 8.55 | 3.31 | +63.34% |
| Q4 2024 | 2024-12-31 | 8.14 | 1.63 | +24.99% |
| Q3 2024 | 2024-09-30 | 9.56 | 3.00 | +45.72% |
| Q2 2024 | 2024-06-30 | 7.77 | 0.87 | +12.59% |
| Q1 2024 | 2024-03-31 | 5.23 | −1.95 | −27.16% |
| Q4 2023 | 2023-12-31 | 6.51 | −0.66 | −9.19% |
| Q3 2023 | 2023-09-30 | 6.56 | −1.94 | −22.86% |
| Q2 2023 | 2023-06-30 | 6.90 | −0.64 | −8.45% |
| Q1 2023 | 2023-03-31 | 7.18 | −0.71 | −8.99% |
| Q4 2022 | 2022-12-31 | 7.17 | −0.59 | −7.58% |
| Q3 2022 | 2022-09-30 | 8.51 | 0.36 | +4.38% |
| Q2 2022 | 2022-06-30 | 7.53 | 2.20 | +41.12% |
| Q1 2022 | 2022-03-31 | 7.89 | — | — |
| Q4 2021 | 2021-12-31 | 7.76 | 5.67 | +271.54% |
| Q3 2021 | 2021-09-30 | 8.15 | — | — |
| Q2 2021 | 2021-06-30 | 5.34 | — | — |
| Q4 2020 | 2020-12-31 | 2.09 | — | — |
TScan Therapeutics current ratio trends
Over the last five fiscal years, TScan Therapeutics's current ratio increased from 2.09 to 8.41, a change of 6.32. The latest reported quarter, Q2 2026, shows 3.37.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review TScan Therapeutics source filings ↗